Madrigal Pharmaceuticals, Inc. (MDGL)

NMS – Real Time Price. Currency in USD

510.26

+13.23 (2.66%)

At close: May 12, 2026, 4:00 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

958M

180M

Cost of goods sold

-58M

-7M

-527K

-467K

Gross Profit

901M

173M

-527K

-467K

Operating expenses (excl. COGS)

-1.20B

-671M

-380M

-293M

Operating Income

-300M

-498M

-380M

-294M

Non-operating income, total

12M

32M

-2M

Pretax income

-288M

-466M

-374M

-295M

Equity in earnings

Taxes

Non-controlling/minority interest

After tax other income/expense

Net income before discontinued operations

-288M

-466M

-374M

-295M

Madrigal Pharmaceuticals, Inc. (MDGL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Madrigal Pharmaceuticals, Inc. (MDGL)

Income Statement (Annual)

Income Statement (Annual)

Search stocks

Madrigal Pharmaceuticals, Inc. (MDGL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Madrigal Pharmaceuticals, Inc. (MDGL)

Income Statement (Annual)

Income Statement (Annual)